About Aminoacyl tRNA synthase complex-interacting multifunctional protein 1
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (AIMP1) is a protein
from Homo sapiens identified by UniProt accession
Q12904, 312 residues long.
MolForge cross-references it against 0 known binders and
140 disease associations.
Target properties
| Protein name | Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 |
| UniProt accession | Q12904 |
| Gene | AIMP1 |
| Organism | Homo sapiens |
| Length | 312 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (140)
Diseases linked to this target (Open Targets).
- hypomyelinating leukodystrophy 3 · score 0.76
- Pelizaeus-Merzbacher-like disease due to AIMP1 mutation · score 0.72
- autosomal recessive non-syndromic intellectual disability · score 0.37
- Hypotonia · score 0.34
- genetic disorder · score 0.19
- FEV/FVC ratio · score 0.12
- neoplasm · score 0.10
- balding measurement · score 0.10
- glioblastoma multiforme · score 0.09
- non-Hodgkins lymphoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12904-F1 | alphafold | PREDICTED | 81.10 | — |
Amino-acid sequence (312 residues)
MANNDAVLKR LEQKGAEADQ IIEYLKQQVS LLKEKAILQA TLREEKKLRV ENAKLKKEIE ELKQELIQAE IQNGVKQIPF PSGTPLHANS MVSENVIQST AVTTVSSGTK EQIKGGTGDE KKAKEKIEKK GEKKEKKQQS IAGSADSKPI DVSRLDLRIG CIITARKHPD ADSLYVEEVD VGEIAPRTVV SGLVNHVPLE QMQNRMVILL CNLKPAKMRG VLSQAMVMCA SSPEKIEILA PPNGSVPGDR ITFDAFPGEP DKELNPKKKI WEQIQPDLHT NDECVATYKG VPFEVKGKGV CRAQTMSNSG IK
Explore Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets